Skip to main content

Table 2 Pathogenic neurofilament-light peptides in ABH mice a

From: Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis

Antigen/peptides

Number with EAE

Mean group scoreb

Mean EAE scorec

Mean day of onset

Panel A

    

SCH

4/4

4.0 ± 0.0*

4.0 ± 0.0

15.3 ± 0.3

rmNF-L

4/5

0.7 ± 0.3*

0.9 ± 0.2

31.0 ± 1.4

241 to 256

1/5

0.1 ± 0.1

0.5 ± N/A

21.0 ± N/A

249 to 264

5/5

0.9 ± 0.3*

0.9 ± 0.3

25.6 ± 6.4

257 to 272

3/5

0.4 ± 0.2

0.7 ± 0.2

29.3 ± 0.6

265 to 280

0/5

N/A

N/A

N/A

273 to 288

0/5

N/A

N/A

N/A

345 to 360

3/5

0.7 ± 0.3

1.2 ± 0.3

29.3 ± 0.3

353 to 368

3/5

0.5 ± 0.2

0.8 ± 0.2

25.7 ± 4.4

Panel B

    

129 to 144

2/5

0.2 ± 0.1

0.5 ± 0.0

18.5 ± 6.5

297 to 312

2/5

0.2 ± 0.1

0.5 ± 0.0

30.5 ± 0.5

313 to 328

0/5

N/A

N/A

N/A

113 to 128, 281 to 296, 289 to 304, 321 to 336 (4)

3/4

0.9 ± 0.4

1.2 ± 0.3

28.7 ± 0.7

201 to 216, 377 to 392, 457 to 472 (3)

0/5

N/A

N/A

N/A

Panel C

    

CFA

0/5

N/A

N/A

N/A

  1. aAnimals were injected with (panel A) 200 μg spinal cord homogenate (SCH), rmNF-L or single immunodominant NF-L peptides in CFA or with (panel B) peptides in Complete Freund’s adjuvant (CFA) predicted to bind H2-Ag7 or with (panel C) CFA alone.
  2. bMean ± standard error of the mean (SEM) of the maximum experimental autoimmune encephalomyelitis (EAE) score of animals in the group.
  3. cMean ± SEM of the maximum EAE score of affected animals.
  4. N/A, not applicable. *P <0.05, compared with CFA immunized mice.